Race for Modov: Modern Vaccines Requires US and European Approval for Widespread Use, After Company Announced “Absolutely Remarkable” End Results – UPDATE – Coronavirus

12/01/2020 Romania

[ad_1]

Moderna has submitted the documents for emergency approval from the relevant US and European institutions so that its Covid vaccine can be recommended for widespread use.

Regulators will review the candidate vaccine test data before deciding whether its administration is safe and effective enough to recommend distribution of the product.

Clinical trials presented by the US company indicated 94% effectiveness in protecting people against the new coronavirus, notes BBC News. Initially, the company announced an efficiency of almost 95% (94.5%).

Only 11 people who received two doses of the Moderna vaccine developed Covid-19 symptoms after being infected with the coronavirus cloud, compared to 185 symptomatic cases in the placebo group, based on final results of the 30,000 vaccine trial. people. Thus, according to the company, the Moderna vaccine has an efficacy of 94.1%.

More impressive is that the vaccine is 100% effective against a severe form of the disease. There were none of those cases.

Pfizer has already applied for approval of its vaccine in the United States.

Currently, there are three main vaccines that have passed testing. However, each has some advantages and disadvantages, the big differences in terms of storage conditions, effectiveness and prices.

The AstraZeneca vaccine is cheaper: £ 3 / dose, compared to £ 15 for the Pfizer vaccine and £ 25 for the Moderna.

However, the efficacy also differs: the AstraZeneca vaccine has a rate of 62-90%, while Moderna and Pfizer have a rate of more than 95%.

[ad_2]

TricksFast News that Matters to You Most

Race for Modov: Modern Vaccines Requires US and European Approval for Widespread Use, After Company Announced “Absolutely Remarkable” End Results – UPDATE – Coronavirus

Related Articles